Suppressor or regulatory T cells (Tregs) have enjoyed a checkered history since the first report of in-vivo suppressor T-cell activity in 1971 . Widespread acceptance of Tregs as a bona fide T-cell subset came only with the identification of a surface marker, CD25 (the alpha chain of the IL-2 receptor), that was constitutively expressed by CD4 T cells with suppressive ability in vivo[2,3]. The demonstration that purified CD4+CD25+ T cells could suppress the proliferation of CD4+CD25− T cells in vitro provided a crucial confirmation of the link between phenotype and function . Importantly, the in-vitro suppression assay could also be applied in human disease . The past decade has seen an explosion of research interest in Tregs, as the tools of modern cellular and molecular immunology have been applied to understanding immune regulation in mouse and humans [6–10]. In particular, the discovery that the transcription factor Foxp3 is highly expressed by Tregs in both species, and is required for their development and function [11–14], has opened the way for elegant studies of Treg biology in mouse models  and for more reliable identification of Tregs in the human . This review will briefly describe the current state of understanding of normal Treg biology, most of which is still based on murine models, and will then detail how Tregs are affected by HIV infection, and how they may influence the course of HIV disease.
Identification of regulatory T cells
As mentioned above, the expression of CD4 and CD25 was initially used to define Tregs in the mouse . As activated CD4 T cells also express CD25, purified CD4+CD25+ Tregs were likely to be contaminated with an unknown proportion of activated conventional T cells. Such contamination did not present a major problem in animals raised in pathogen-free conditions, as the number of conventional CD4 T cells expressing CD25 was usually small compared with the number of Tregs. Murine studies have continued to use CD25 as the principal marker for the isolation of viable Tregs, whereas FoxP3 expression is more commonly regarded as the most definitive marker after cell fixation (Table 1).
In contrast to the mouse, human circulating effector/memory CD4 T cells express CD25 at a level only slightly lower than that of Tregs , and this finding has presented a major obstacle to the accurate identification of human Tregs. To avoid massive contamination of purified human Tregs with memory cells, investigators initially chose to study the relatively pure minority Treg subpopulation expressing the highest level of CD25 . Human Tregs have also been identified by the expression of a number of molecules that, although not exclusive to the Treg subset, are either more highly or more uniformly expressed when compared with conventional CD4 T cells (Table 1). These molecules include members of two families of co-stimulatory molecules: the CD28 superfamily, represented by cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and inducible co-stimulator protein, and the tumor necrosis factor receptor superfamily, represented by CD27, OX40, 4-1BB and glucocorticoid-induced tumor necrosis factor receptor (GITR) family-related protein.
In addition, human Tregs have been subdivided according to their activation state. Most Tregs in neonates are CD45RA-positive, whereas the majority in adults express CD45RO. The presence of a discrete population of CD45RA-positive Tregs in adults has also recently been described by several groups [17–19]. These naive Tregs probably comprise that part of the peripheral Treg repertoire that has not received sufficient T-cell receptor stimulation to convert to the expression of CD45RO. In general, CD45RA-positive Tregs express CD25 and co-stimulatory molecules at lower levels than CD45RO-positive Tregs, indicative of a lower ‘activation’ status .
Two recent technical advances have improved the identification and isolation of the majority of human Tregs that do not express the highest levels of CD25. The generation of anti-FoxP3 monoclonal antibodies allowed Tregs to be identified after fixation and permeabilization , whereas the surface CD127loCD25+ phenotype was shown to be highly correlated with intracellular Foxp3 expression, providing a means of purifying viable human Tregs [20,21]. It should be noted, however, that FoxP3 expression is not always indicative of regulatory status within human CD4 T cells [17,40–44].
Mechanism of regulatory T cell function
Most of our knowledge of in-vivo Treg function comes from murine models. Tregs are involved in virtually every stage of the adaptive immune response. They thus not only prevent the activation of self-reactive cells, but downregulate responses to foreign antigen at the expansion and effector stages (Table 2). Blocking Treg function in vivo has been shown to stimulate rejection of otherwise tolerated tumors  and to allow the clearance of chronic infections under some experimental conditions . Despite their potent in-vivo activity, the mechanism of murine Treg suppressive activity remains unclear, with evidence both for and against the involvement of transforming growth factor beta (TGF-β), IL-10, CTLA-4, target cell killing and the induction of indoleamine 2,3-dioxygenase (IDO) production by dendritic cells and macrophages [25,26,47–52]. IDO is an enzyme that degrades tryptophan to kynurenine. IDO activity not only deprives T cells of an essential amino acid, but drives the production of immunosuppressive tryptophan metabolites .
Suppression of CD25− responder T-cell proliferation to an artificial polyclonal stimulus such as anti-CD3 monoclonal antibody has been widely adopted as the definitive assay for murine Treg function. In these cell co-culture assays, the secretion of TGF-β and IL-10 by Tregs can usually be detected. In-vitro suppression is not, however, dependent on soluble factors, but requires physical contact between Tregs and responder T cells, involving an as yet undefined molecular mechanism . On the basis of these findings, it was surprising that murine Tregs mediating in-vivo regulatory function were recently shown not to contact responder T cells . To add to concerns about the validity of the in-vitro suppression assay, a number of recent reports have detected normal in-vitro suppressive function mediated by Tregs derived from gene knockout mice with major deficits in self-tolerance and in-vivo regulatory function [56,57].
In-vitro interactions between murine Tregs and dendritic cells have been reported to reduce dendritic cell expression of co-stimulatory molecules, which could explain how they downregulate multiple aspects of immune activation and differentiation [58–60]. Whether this is achieved by means of soluble mediators or cell–cell interaction remains an open question. Treg–dendritic cell interaction mediated via CTLA-4 ligation of CD80/86 has been shown to induce IDO production by dendritic cells . This mechanism accounts at most for only part of the spectrum of Treg functions, because IDO knockout mice do not manifest an autoimmune phenotype , in contrast to FoxP3 knockout mice with no Tregs .
Human studies of Treg function have of necessity been limited to in-vitro testing. Human Tregs can suppress polyclonal stimulation of conventional T cells (usually CD25− cells stimulated with anti-CD3 with or without anti-CD28 or allogeneic non-T cells as antigen-presenting cells). Like murine Tregs, human Tregs make soluble immunosuppressive mediators such as TGF-β and IL-10, but require cell–cell contact with target cells to function in vitro. Once again, the molecular mechanism underlying suppression is still highly controversial.
In the early studies of Baecher-Allen et al. reliable suppressive activity was limited to the CD25high population. With the removal of contaminating CD25intCD45RO+ conventional T cells, we have now shown that CD25int Tregs have equally potent suppressive activity , as have CD45RA-positive naive Tregs . It seems counterintuitive that naive and effector memory Tregs should have the same functional activity, given the clear in-vitro differences between conventional naive and effector memory cells. Furthering our understanding of how Tregs function at a cellular and molecular level is clearly one of the major challenges currently facing the field.
Selection and specificity of regulatory T cells
Elegant genetic studies using green fluorescent protein to mark Foxp3+ Tregs in vivo have shown that Tregs arise in the thymus after selection for intermediate affinity recognition of self-antigen, which drives the expression of CD25 and then Foxp3 . Tregs can also be generated de novo from naive peripheral CD25−CD4+ T cells after prolonged low avidity stimulation  or in skin graft recipients treated with non-depleting anti-CD4 antibodies , but the ongoing contributions of these peripheral pathways to the adult repertoire of Tregs remain unknown. In vitro, TGF-β can drive the differentiation of naive murine CD25−CD4+ T cells to a Foxp3+ suppressive phenotype  and recent in-vitro and in-vivo evidence supports a role for a combination of TGF-β and all-trans retinoic acid, a metabolite of vitamin A, in de novo Treg differentiation, particularly in the gut [66–69].
The antiself specificity of peripheral Tregs has not been formally demonstrated in normal mice, because of the technical difficulty inherent in detecting these intermediate affinity T-cell receptor interactions. Foxp3+ Tregs with defined specificity for foreign antigen have, however, been isolated from peripheral lymphoid and non-lymphoid tissues. In particular, murine Tregs specific for Leishmania major[46,70], and allo-major histocompatibility complex antigens  have been well characterized. These cells could be derived from self-reactive thymic Tregs that crossreact against foreign antigen, or from peripheral Foxp3− cells. It was recently demonstrated that at least some of the Leishmania-specific FoxP3+Tregs are the descendants of peripheral CD25+CD4+ T cells , but whether they first expressed FoxP3 in the thymus or in the periphery remains unknown.
FoxP3+ T cells are present in human thymus and cord blood , suggesting a similar differentiation and selection mechanism to that in the mouse. Whereas FoxP3 expression appears to lag behind the expression of CD25 in the mouse, approximately half the FoxP3+ cells in the human infant thymus are CD25−, once again underlining the differences in FoxP3 expression between the species. Self-reactive specificities within human Treg populations have not been demonstrated experimentally, but several studies have documented reactivity against well-defined foreign antigens, including hepatitis C virus (HCV) . Once again, whether antiforeign reactivity represents a crossreactive specificity of a Treg with antiself specificity, or whether it reflects differentiation from a peripheral antiforeign conventional T cell is not known. In-vitro differentiation from naive human CD4 T cells in the presence of TGF-β , vitamin D  or prostaglandin E2  induces FoxP3 expression and suppressive function, and these pathways may also be used to generate Tregs in vivo, particularly during ongoing responses in the gut. Our own unpublished data (Fazekas de St Groth, Smialkowski and Dervish) derived from paired biopsies of involved versus uninvolved bowel mucosa in ulcerative colitis patients have shown a positive correlation between the presence of an inflammatory infiltrate and both the percentage and absolute number of CD4+FoxP3+ T cells. These data are consistent with a model in which the increases in FoxP3+ T cells within the gut lamina propria in conditions such as inflammatory bowel disease are secondary to the inflammatory process, operating as a negative feedback loop to control the adverse effects of inflammation (Table 2).
Molecules involved in regulatory T cell biology in vivo
Studies using genetically modified mice have provided many insights into the factors required to generate and maintain normal populations of Tregs. Understanding these factors is essential if we are to understand how Tregs are involved in immune responses to pathogens such as HIV.
IL-2 is required for normal Treg function in addition to its role in the maintenance of Treg numbers. Mice lacking IL-2 , IL-2Rα  or IL-2Rβ  have profound regulatory abnormalities, although CD4+Foxp3+ T-cell numbers are only modestly reduced . The expression of CD25 by Foxp3+ cells is markedly decreased in IL-2-deficient mice, and the administration of IL-2 rapidly normalizes CD25 expression via the Stat5 pathway  and increases Foxp3 expression per cell . IL-2 is essential for normal Treg function in vitro, as demonstrated by experiments in which the addition of anti-IL-2 monoclonal antibodies blocked suppression in co-cultures of Treg and conventional Tcells [81,82].
Recent clinical trials involving the administration of IL-2 have reported increases in circulating Treg numbers, particularly within the CD45RA compartment, indicating that human Treg viability is also supported by IL-2 [83–87]. IL-2 also increases FoxP3 expression within sorted CD4+CD25+ T cells in vitro via the classical STAT3/STAT5 signalling pathway .
Transforming growth factor beta
The role of TGF-β in Treg biology is complex. Mice deficient in TGF-β or its receptor develop multiorgan inflammation and die at a young age . Both conventional and regulatory T cells make TGF-β and the normal maintenance of self-tolerance requires that both subsets also express functional TGF-β receptors . Whether TGF-β is directly involved in mediating Treg function remains controversial [39,57]. Certainly TGF-β treatment of murine Foxp3− cells can induce both Foxp3 expression and regulatory function in vitro.
TGF-β treatment can also convert human Foxp3− cells to a suppressive, FoxP3+ phenotype in vitro. Consistent with the high TGF-β levels in the gut, increased numbers of Tregs in the gut mucosa have been documented in human inflammatory bowel disease (IBD)  and in HIV infection (see below). As mentioned above, our own data from IBD patients indicate that Tregs increase in proportion to the degree of inflammation in the bowel mucosa, suggesting that they are responding to inflammatory stimuli. Increases in Tregs are, however, not a universal accompaniment of bowel inflammation, as Treg numbers in the gut are reduced in graft versus host disease . Whether human gut mucosal Tregs are induced in situ from Foxp3− cells or derived from circulating Foxp3+ cells remains to be determined, although recent reports concerning the effects of TGF-β and retinoic acid in the murine gut (above) strongly suggest in-situ induction.
Cytotoxic T-lymphocyte-associated protein 4 and indoleamine 2,3-dioxygenase
CTLA-4-deficient mice develop a rapidly fatal lymphoproliferative syndrome that can be overcome by the provision of wild-type bone marrow in mixed chimeras, indicating that CTLA-4-deficient Tregs cannot mediate normal regulatory function in vivo. This finding is paradoxical, because CTLA-4 transmits a negative rather than a positive signal, so its absence should enhance rather than inhibit the function of cells that express it. It has been postulated that CTLA-4 must therefore serve different functions in Tregs and conventional T cells. One such alternative function of CTLA-4 is to induce dendritic cells to express IDO, thus inhibiting T-cell proliferation as mentioned above . Recent in-vitro evidence indicates that IDO may also function to induce de novo FoxP3 expression in CD4 T cells, suggesting that CTLA-4 and IDO may be part of a positive feedback loop between dendritic cells and Tregs .
Anti-CTLA-4 antibody is in clinical trial as a stimulant of antitumor immune responses . Potentially life-threatening immune-related adverse events (IRAE) such as colitis, hypophysitis and adrenal insufficiency have been noted in a substantial number of patients in those trials, consistent with the postulated role of CTLA-4 as a mediator of Treg function [94,95]. Fortunately, these IRAE are generally reversible with standard anti-inflammatory therapy. A requirement for CTLA-4 expression during TGF-β-dependent induction of Foxp3 in naive human CD4 T cells has recently been demonstrated in vitro, linking CTLA-4 with the peripheral pathway of Treg generation in addition to its role in the function of Tregs differentiated in the thymus. There is also evidence for the bi-directional link between CTLA-4 and IDO mentioned above. CTLA-4 has thus been shown to induce the production of IDO by human dendritic cells [97,98] and conversely IDO can convert human CD4+CD25− T cells to CD4+CD25−FoxP3+ cells .
PD-1 and regulatory T cells
PD-1 is an inhibitory receptor expressed on the surface of differentiated effector T cells in both the mouse and human [100,101]. It has recently been shown that the expression of PD-1 by CD8 T cells in chronic infections such as HIV is associated with decreased cytotoxic activity [102–104]. The expression of PD-1 in Foxp3+ Tregs is restricted to the cytoplasm, but surface expression can be induced by activation in vitro. The role of PD-1 expression in Treg function is currently not known.
Regulatory T cells as part of a normal feedback loop in inflammation
There is increasing evidence that FoxP3+ Tregs are overrepresented as a proportion of CD4 T cells at inflammatory sites in both the mouse and human. The best evidence for such increases is in IBD . As mentioned above, whether such cells are derived directly from the thymus or are induced in the periphery is unknown. Certainly, IDO expression is also upregulated at these sites and may be part of the positive feedback loop described above.
Do regulatory T cells prevent clearance of infectious organisms?
Healed Leishmania skin lesions in resistant mice contain a high proportion of Tregs and a few viable organisms . The transfer of Leishmania-specific T cells depleted of Tregs can produce sterilizing immunity in immunodeficient mice, suggesting that Tregs prevent full clearance under normal conditions . Importantly, however, Tregs neither prevent healing of the skin lesion, nor are they implicated in lesion spread in susceptible mouse strains.
Human hepatitis C virus
It has been suggested that excessive Treg activity may be associated with the induction and maintenance of the HCV carrier state, based on evidence that Treg numbers are increased in the peripheral blood of HCV-infected patients  and that the specificity of Tregs for HCV antigens can be demonstrated . Among HCV-infected individuals, however, liver enzyme levels and hepatic damage correlate with lower rather than higher Treg numbers, consistent with a protective rather than pathogenic role of Tregs in HCV . In chimpanzees, Tregs are equally high in chronic HCV carriers and spontaneously recovered animals . It thus appears unlikely that Tregs are entirely responsible for the carrier state in HCV infection.
Regulatory T cells in HIV
It has been suggested that excessive Treg activity may be responsible for establishing a carrier state in HIV-infected individuals. HIV infection is accompanied by an early loss of immune function affecting multiple cell types , which could conceivably be caused by abnormally high regulatory activity.
Regulatory T-cell numbers in HIV infection
The number of Tregs detected in samples from HIV-infected patients is influenced by a number of factors, including the tissue sampled, the stage of infection, and whether antiretroviral therapy (ART) has been instituted. Table 3 summarizes a number of reports of Treg numbers in peripheral blood, tonsils, lymph nodes and duodenal mucosa of HIV-infected patients and SIV-infected rhesus macaques. The picture has been complicated by the use of different Treg detection methods in different laboratories, each with their individual sources of error (Table 1). For example, the use of a CD4+CD25+ gating strategy would result in different levels of contamination by activated CD4 T cells, depending on the clinical status of the patient. Alternatively, the CD4+CD25hi gate underestimates total Treg numbers by up to sixfold in normal individuals  and by an unknown proportion in HIV-infected individuals. Until recently, Foxp3 expression was estimated only by polymerase chain reaction for Foxp3 messenger RNA, usually without full quantitation. Characteristic Treg markers such as CTLA-4 and GITR have also been used as indirect measures of Treg number and activity, but once again are also expressed by a subset of activated CD4 T cells. The use of standardized multicolor antibody cocktails for Treg identification and purification (Table 1) should rapidly increase the precision with which we can estimate Treg numbers, phenotype and function in HIV infection.
A consensus is beginning to emerge as more studies of Tregs in HIV are published and compared with the data from the SIV model. In lymphoid tissues such as the tonsil [114,122], a large increase in Tregs, detected by immunohistochemical staining for Foxp3 expression, has been reported (Table 3). Expression of CD25 by these Foxp3+ cells is lower than in blood or mucosa [114,122]. Like the tonsil, lymph nodes from untreated HIV-infected individuals contain an unusually high number of Tregs and dendritic cells with a semi-mature phenotype and the ability to induce Foxp3 expression in vitro.
In the gut, which is a site of primary HIV and SIV infection associated with early and prolonged CD4 T-cell depletion [123,124], the absolute number of CD4+Foxp3+ Tregs increases during infection by HIV  and SIV . Up to 50% of total mucosal CD4 T cells express Foxp3 in some treatment-naive individuals .
Several mechanisms that may explain HIV-related increases in Tregs have recently been reported (Fig. 1). Zaunders et al. have provided evidence that CD4+CD127lo T cells are relatively spared in HIV infection, compared with conventional CD4+CD127hi T cells. Survival of Tregs may be a consequence of the ability of FoxP3 to repress retroviral transcription from the HIV promoter, partly by blocking the activation of nuclear factor kappa B . Nilsson et al. recently showed that HIV gp120 could increase Foxp3 expression in cultured CD4+Foxp3+ T cells, while inhibiting their apoptosis. Hsieh et al. have suggested that one of the effects of HIV-1 Tat on dendritic cells is to increase CTLA-4 expression and the suppressive potency of Tregs. A fourth possibility is that the increase is a natural response to inflammation at the site, analogous to the situation in IBD (see above).
The institution of ART has been shown to reduce markedly the number of Tregs in tonsils  and duodenal mucosa , but not in lymph nodes . Whether this is a direct consequence of reduced viral load or a secondary effect of decreased inflammation is not yet clear.
In peripheral blood, a number of groups have reported minor increases in the percentage of Tregs within the CD4 T-cell compartment in subgroups of HIV-infected individuals [110–113,115,116,119,120], whereas others have seen no change  (Table 3). In general, individuals with the largest increases in Tregs as a proportion of CD4 T cells have CD4 T-cell counts below 200 cells/μl, and high viral loads, although the Treg percentages in this very lymphopenic group tend to be highly variable [110,113,114,116,120]. Blood Treg percentages tend to normalize after the institution of ART , consistent with the data from the gut and tonsils.
Several studies have shown decreases in FoxP3 mRNA in peripheral blood T cells of patients with high viral loads or low CD4 T-cell counts [110,114–116], despite increases in the proportion of CD4+CD25hi T cells. A decrease in FoxP3 expression per cell suggests that regulatory function may be compromised. The decrease may be secondary to a relative deficiency in IL-2, which has been shown to control FoxP3 transcription (see above). FoxP3 mRNA levels normalize with ART [114,120].
Functional assays of regulatory T cells in HIV infection
Initial studies of Treg function involved the comparison of in-vitro peripheral blood T-cell responses to HIV and to co-infections such as cytomegalovirus and Mycobacterium tuberculosis with and without the depletion of Tregs, and in some cases with the addition of purified CD4+CD25+ T cells [111,112,115,128,129] (Table 4). These studies indicated that Treg activity was retained in HIV infection, but did not determine its potency compared with the level in uninfected individuals. Early studies of peripheral blood regulatory activity suggested a decrease in patients with high viral loads and low CD4 T-cell numbers [111,115]. Similar conclusions were drawn from studies of infants, of whom those who were HIV infected had fewer Tregs and a smaller increase in HIV-specific CD8 T-cell responses after Treg depletion than exposed uninfected infants . A recently published study has, however, provided definitive evidence that Tregs in lymph nodes retain potent suppressive activity even in late disease and in the face of high viral loads . That study confirmed the decrease in FoxP3 expression and regulatory activity in the blood of infected individuals.
It is still unclear whether excessive Treg activity prevents an effective anti-HIV response at sites of primary infection such as the gut (Table 2). Further functional studies will be required to understand the impact of Tregs at different sites on the clearance of virus within the body as a whole.
Regulatory T cells in animal models of HIV
Correlations between changes in Treg activity and the pathogenicity of acute SIV infection of rhesus macaques, a susceptible species, and sooty mangabeys and African green monkeys, both resistant species, have failed to resolve the question of whether Tregs promote or prevent SIV-mediated disease. SIV infection in African green monkeys is accompanied by increased CD4+CD25+ T-cell frequency, FoxP3 expression and TGF-β secretion, compared with pathogenic SIV in macaques . A comparison of SIV infection in macaques and sooty mangabeys, however, indicated a positive rather than a negative correlation between viral pathogenicity, immune activation, Treg activity, TGF-β levels and lymphatic tissue fibrosis . Estes et al. have reported dramatic increases in the frequency of CD4+CD25+Foxp3+ T cells in the T cell zones of lymph nodes in SIV infection of macaques, accompanied by increases in T cells producing TGF-β, IL10 and IDO. In comparison, more modest increases in Treg frequency and immune activation were seen in rhesus cytomegalovirus infection.
A trial of anti-CTLA-4 monoclonal antibody treatment of rhesus macaques with acute SIV produced a decrease in viral load, an increase in effector function and a decrease in IDO and TGF-β levels suggestive of reduced Treg activity, prompting the conclusion that Tregs were exerting a detrimental effect . Similarly, in a model in which an encephalitis sharing features with HIV encephalitis in humans was produced in immunodeficient mice reconstituted with human peripheral blood lymphocytes and given an intracranial injection of HIV-infected monocyte-derived macrophages, treatment with the IDO inhibitor, 1-methyl-D-tryptophan led to an increase in HIV-specific CD8 T cells and the elimination of infected macrophages, suggesting a role for IDO and, by extension, Tregs, in maintaining chronic infection .
Regulatory T cells and the design of future therapies
Ablative therapies that directly target regulatory T cells
Reducing Treg numbers or activity in vivo is likely to increase specific anti-HIV T-cell responses, whether or not Tregs are directly responsible for HIV-dependent immunodeficiency and the failure to control viral load. Testing treatments that target Tregs is most advanced in the field of cancer immunotherapy, with anti-CTLA-4  and an IL-2 toxin conjugate  tested in clinical trials. Those studies have highlighted the potential for Treg ablation to precipitate severe autoimmune sequelae, including grade III/IV IRAE necessitating cessation of the therapy (see above and Weber ). The gut is the commonest site of major side effects, indicating the important role that Tregs play in maintaining normal immune homeostasis in the gut. Anti-CTLA-4 in particular appears to be both the most potent and the most likely to produce side effects, probably because it simultaneously reduces Treg activity and blocks intrinsic negative signals in activated high-affinity T cells. The positive effects of anti-CTLA-4 monoclonal antibody treatment of rhesus macaques with acute SIV  provide support for the application of anti-CTLA-4 therapy to HIV infection.
Increasing effector T-cell activity by targeting PD-1 may also be effective, if it can be demonstrated that the activity of Tregs is not increased by this manoeuvre .
Treg ablation therapy could be designed for use at different stages of HIV infection, either alone or in combination with ART: in primary disease, in the hope of generating the type of immunity that operates in long-term non-progressors, combined with therapeutic vaccination, as in some of the cancer therapy trials, or with other novel agents such as antibodies directed to the co-stimulator 4-1BB .
Therapies that change the balance between regulatory T cells and other T-cell subsets
Both low and high-dose IL-2 therapy increase Treg numbers, particularly in the CD45RO-negative compartment, and increase the activation status of CD45RO-positive Tregs [83,84,86,87]. As mentioned above, IL-2 is known to increase the expression of Foxp3, which is associated with increased Treg activity in vitro. IL-2 is, however, also a potent stimulant of CD8 T-cell activity, particularly when conventional CD4 T-cell numbers are low. The effects of IL-2 may therefore differ at different stages of HIV infection, depending on the balance between regulatory and effector activity.
As most conventional T cells express high levels of IL-7 receptor whereas Tregs do not, IL-7 therapy offers the prospect of supporting T-cell reconstitution during ART without increasing Treg numbers or activity. IL-7 receptor expression by conventional T cells is, however, abnormally low in HIV infection , possibly as a result of downregulation in response to increased serum IL-7 levels . In addition, IL-7 has been reported to increase HIV replication, although this may be secondary to increased T-cell viability [143,144]. In the first report of the effects of IL-7 therapy in cancer patients , both CD4 and CD8 T-cell numbers increased whereas the percentage of Tregs decreased. IL-7 therapy of SIV-infected rhesus macaques has also shown promise when combined with ART, supporting increases in CD4 and CD8 T-cell numbers in the naive and memory compartments . The use of IL-7, possibly in combination with IL-2 or anti-CTLA-4, thus offers the prospect of resetting the balance of regulation in HIV disease.
In conclusion, the interplay between Tregs and conventional T cells is a complex one. Tregs are involved in virtually every immune response and appear to function as a network of controlling and tuning circuits imposed above the primary activation circuits. Whereas the removal of Tregs reliably increases virtually every immune response so far tested, this increase come at a price – that of dysregulation, which may manifest as autoimmune disease or an increase in the immunopathology accompanying infectious disease. We need to understand more about the cause and effect relationships between Tregs, conventional T cells and HIV to judge whether Treg depletion will prove useful in the treatment of HIV, and whether it should be combined with other novel therapies such as the blockade of PD-1.
Conflicts of interest: None.
1. Gershon RK, Kondo K. Infectious immunological tolerance. Immunology 1971; 21:903–914.
2. Hall BM, Pearce NW, Gurley KE, Dorsch SE. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+
suppressor cell and its mechanisms of action. J Exp Med 1990; 171:141–157.
3. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor a-chains (CD25); breakdown of a single mechanism. J Immunol 1995; 155:1151–1164.
4. Thornton AM, Shevach EM. CD4+
immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998; 188:287–296.
5. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+
regulatory cells in human peripheral blood. J Immunol 2001; 167:1245–1253.
6. Shevach EM. CD4+
suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2:389–400.
7. Fehervari Z, Sakaguchi S. CD4+
Tregs and immune control. J Clin Invest 2004; 114:1209–1217.
8. Bluestone JA. Regulatory T-cell therapy: is it ready for the clinic? Nat Rev 2005; 5:343–349.
9. Shevach EM. From vanilla to 28 flavors: Multiple varieties of regulatory T cells. Immunity 2006; 25:195–201.
10. Boasso A, Vaccari M, Nilsson J, Shearer GM, Andersson J, Cecchinato V, et al
. Do regulatory T-cells play a role in AIDS pathogenesis. AIDS Rev 2006; 8:141–147.
11. Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgaropoulos C, Helms C, Bowcock AM. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 2000; 106:R75–R81.
12. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, et al
. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001; 27:18–20.
13. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, et al
. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27:20–21.
14. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, et al
. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001; 27:68–73.
15. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005; 6:331–337.
16. Roncador G, Brown PJ, Maestre L, Hue S, Martinez-Torrecuadrada JL, Ling KL, et al
. Analysis of FOXP3 protein expression in human CD4+
regulatory T cells at the single-cell level. Eur J Immunol 2005; 35:1681–1691.
17. Seddiki N, Santner-Nanan B, Tangye SG, Alexander SI, Solomon M, Lee S, et al
. Persistence of naive CD45RA+
regulatory T cells in adult life. Blood 2006; 107:2830–2838.
18. Valmori D, Merlo A, Souleimania N, Hesdorffer C, Ayyoub M. A peripheral circulating compartment of natural naive CD4 Tregs. J Clin Invest 2005; 115:1953–1962.
19. Fritzsching B, Oberle N, Pauly E, Geffers R, Buer J, Poschl J, et al
. Naive regulatory T cells: a novel subpopulation defined by resistance toward CD95L-mediated cell death. Blood 2006; 108:3371–3378.
20. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, et al
. Expression of IL-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203:1693–1700.
21. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al
. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+
T reg cells. J Exp Med 2006; 203:1701–1711.
22. Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T. Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. J Exp Med 1985; 161:72–87.
23. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005; 22:329–341.
24. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057–1061.
25. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+
regulatory cells that control intestinal inflammation. J Exp Med 2000; 192:295–302.
26. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, et al
. Immunologic self-tolerance maintained by CD25+
regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000; 192:303–309.
27. McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, Byrne MC. CD4+
immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002; 16:311–323.
28. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25+
regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002; 3:135–142.
29. Fisson S, Darrasse-Jeze G, Litvinova E, Septier F, Klatzmann D, Liblau R, Salomon BL. Continuous activation of autoreactive CD4+
regulatory T cells in the steady state. J Exp Med 2003; 198:737–746.
30. Choi BK, Bae JS, Choi EM, Kang WJ, Sakaguchi S, Vinay DS, Kwon BS. 4-1BB-dependent inhibition of immunosuppression by activated CD4+
T cells. J Leukoc Biol 2004; 75:785–791.
31. Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL. Phenotypically distinct subsets of CD4+
T cells induce or protect from chronic intestinal inflammation in C.B17 scid
mice. Int Immunol 1993; 5:1461–1471.
32. Gavin MA, Clarke SR, Negrou E, Gallegos A, Rudensky A. Homeostasis and anergy of CD4+
suppressor T cells in vivo
. Nat Immunol 2002; 3:33–41.
33. Lehmann J, Huehn J, de la Rosa M, Maszyna F, Kretschmer U, Krenn V, et al
. Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+
as well as CD25−
regulatory T cells. Proc Natl Acad Sci U S A 2002; 99:13031–13036.
34. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4+
T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193:1285–1294.
35. Scotto L, Naiyer AJ, Galluzzo S, Rossi P, Manavalan JS, Kim-Schulze S, et al
. Overlap between molecular markers expressed by naturally occurring CD4+
regulatory T cells and antigen specific CD4+
T suppressor cells. Hum Immunol 2004; 65:1297–1306.
36. Ruprecht CR, Gattorno M, Ferlito F, Gregorio A, Martini A, Lanzavecchia A, Sallusto F. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med 2005; 201:1793–1803.
37. Ma BY, Mikolajczak SA, Danesh A, Hosiawa KA, Cameron CM, Takaori-Kondo A, et al
. The expression and the regulatory role of OX40 and 4-1BB heterodimer in activated human T cells. Blood 2005; 106:2002–2010.
38. Baecher-Allan C, Wolf E, Hafler DA. MHC class II expression identifies functionally distinct human regulatory T cells. J Immunol 2006; 176:4622–4631.
39. Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N, Nawata H, Strober W. TGF-beta 1 plays an important role in the mechanism of CD4+
regulatory T cell activity in both humans and mice. J Immunol 2004; 172:834–842.
40. Walker MR, Kasprowicz DJ, Gersuk VH, Benard A, Van Landeghen M, Buckner JH, Ziegler SF. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+
T cells. J Clin Invest 2003; 112:1437–1443.
41. Morgan ME, van Bilsen JH, Bakker AM, Heemskerk B, Schilham MW, Hartgers FC, et al
. Expression of FOXP3 mRNA is not confined to CD4+
T regulatory cells in humans. Hum Immunol 2005; 66:13–20.
42. Allan SE, Passerini L, Bacchetta R, Crellin N, Dai M, Orban PC, et al
. The role of 2 FOXP3 isoforms in the generation of human CD4 Tregs. J Clin Invest 2005; 115:3276–3284.
43. Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE. Transient expression of FOXP3 in human activated nonregulatory CD4+
T cells. Eur J Immunol 2007; 37:129–138.
44. Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, Stray-Pedersen A, et al
. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A 2006; 103:6659–6664.
45. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+
T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999; 163:5211–5218.
46. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+
regulatory T cells control Leishmania major
persistence and immunity. Nature 2002; 420:502–507.
47. Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+
regulatory T cells. J Exp Med 2005; 201:1061–1067.
48. Li MO, Sanjabi S, Flavell RA. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T-cell-dependent and-independent mechanisms. Immunity 2006; 25:455–471.
49. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999; 190:995–1003.
50. Zhang X, Koldzic DN, Izikson L, Reddy J, Nazareno RF, Sakaguchi S, et al
. IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+
regulatory T cells. Int Immunol 2004; 16:249–256.
51. Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ. Cutting edge: contact-mediated suppression by CD4+
regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 2005; 174:1783–1786.
52. Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, et al
. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003; 4:1206–1212.
53. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007; 117:1147–1154.
54. Shevach EM, DiPaolo RA, Andersson J, Zhao DM, Stephens GL, Thornton AM. The lifestyle of naturally occurring CD4+
regulatory T cells. Immunol Rev 2006; 212:60–73.
55. Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P, et al
. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 2006; 7:83–92.
56. Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Bluestone JA. Distinct roles of CTLA-4 and TGF-beta in CD4+
regulatory T cell function. Eur J Immunol 2004; 34:2996–3005.
57. Kullberg MC, Hay V, Cheever AW, Mamura M, Sher A, Letterio JJ, et al
. TGF-beta1 production by CD4+
regulatory T cells is not essential for suppression of intestinal inflammation. Eur J Immunol 2005; 35:2886–2895.
58. Cederbom L, Hall H, Ivars F. CD4+
regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 2000; 30:1538–1543.
59. Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Cutting edge: human CD4+
T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 2004; 172:4676–4680.
60. Taams LS, van Amelsfort JM, Tiemessen MM, Jacobs KM, de Jong EC, Akbar AN, et al
. Modulation of monocyte/macrophage function by human CD4+
regulatory T cells. Hum Immunol 2005; 66:222–230.
61. Mellor AL, Baban B, Chandler P, Marshall B, Jhaver K, Hansen A, et al
. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 2003; 171:1652–1655.
62. Fontenot JD. Foxp3 programs the development and function of CD4+
regulatory T cells. Nat Immunol 2003; 4:330–336.
63. Apostolou I, von Boehmer H. In vivo instruction of suppressor commitment in naive T cells. J Exp Med 2004; 199:1401–1408.
64. Cobbold SP, Castejon R, Adams E, Zelenika D, Graca L, Humm S, Waldmann H. Induction of foxP3+
regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. J Immunol 2004; 172:6003–6010.
65. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al
. Conversion of peripheral CD4+
naive T cells to CD4+
regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198:1875–1886.
66. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, Cheroutre H. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007; 317:256–260.
67. Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, Hall J, Sun CM, Belkaid Y, Powrie F. A functionally specialized population of mucosal CD103+
DCs induces Foxp3+
regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 2007; 204:1757–1764.
68. Sun CM, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR, Belkaid Y. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med 2007; 204:1775–1785.
69. Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 2007; 204:1765–1774.
70. Suffia IJ, Reckling SK, Piccirillo CA, Goldszmid RS, Belkaid Y. Infected site-restricted Foxp3+
natural regulatory T cells are specific for microbial antigens. J Exp Med 2006; 203:777–788.
71. Trenado A, Charlotte F, Fisson S, Yagello M, Klatzmann D, Salomon BL, Cohen JL. Recipient-type specific CD4+
regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 2003; 112:1688–1696.
72. Li S, Jones KL, Woollard DJ, Dromey J, Paukovics G, Plebanski M, Gowans EJ. Defining target antigens for CD25+FOXP3+IFN-gamma− regulatory T cells in chronic hepatitis C virus infection
. Immunol Cell Biol
2007; In press.
73. Yamagiwa S, Gray JD, Hashimoto S, Horwitz DA. A role for TGF-b in the generation and expansion of CD4+
regulatory T cells from human peripheral blood. J Immunol 2001; 166:7282–7289.
74. Penna G, Roncari A, Amuchastegui S, Daniel KC, Berti E, Colonna M, Adorini L. Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+
regulatory T cells by 1,25-dihydroxyvitamin D3. Blood 2005; 106:3490–3497.
75. Baratelli F, Lin Y, Zhu L, Yang SC, Heuze-Vourc'h N, Zeng G, et al
. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+
T cells. J Immunol 2005; 175:1483–1490.
76. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993; 75:253–261.
77. Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt FW. Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995; 3:521–530.
78. Suzuki H, Kundig TM, Furlonger C, Wakeham A, Timms E, Matsuyama T, et al
. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 1995; 268:1472–1476.
79. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6:1142–1151.
80. Nakajima H, Liu XW, Wynshaw-Boris A, Rosenthal LA, Imada K, Finbloom DS, et al
. An indirect effect of Stat5a in IL-2-induced proliferation: a critical role for Stat5a in IL-2-mediated IL-2 receptor alpha chain induction. Immunity 1997; 7:691–701.
81. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM. IL-2 is critically required for the in vitro activation of CD4+
T cell suppressor function. J Immunol 2004; 172:6519–6523.
82. De la Rosa M, Rutz S, Dorninger H, Scheffold A. Interleukin-2 is essential for CD4+
regulatory T cell function. Eur J Immunol 2004; 34:2480–2488.
83. Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, Fleisher TA, et al
. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+
regulatory T cells. Nat Med 2005; 11:1238–1243.
84. Sereti I, Imamichi H, Natarajan V, Imamichi T, Ramchandani MS, Badralmaa Y, et al
. In vivo expansion of CD4+
T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest 2005; 115:1839–1847.
85. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+
regulatory T cells in cancer patients. Blood 2006; 107:2409–2414.
86. Shah MH, Freud AG, Benson DM Jr, Ferkitich AK, Dezube BJ, Bernstein ZP, Caligiuri MA. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer. Clin Cancer Res 2006; 12:3993–3996.
87. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, et al
. IL-2 regulates FOXP3 expression in human CD4+
regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo
. Blood 2006; 108:1571–1579.
88. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, et al
. Transforming growth factor beta1
null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A 1993; 90:770–774.
89. Holmen N, Lundgren A, Lundin S, Bergin AM, Rudin A, Sjovall H, Ohman L. Functional CD4+
regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm Bowel Dis 2006; 12:447–456.
90. Rieger K, Loddenkemper C, Maul J, Fietz T, Wolff D, Terpe H, et al
. Mucosal FOXP3+
regulatory T cells are numerically deficient in acute and chronic GvHD. Blood 2006; 107:1717–1723.
91. Bachmann MF, Kohler G, Ecabert B, Mak TW, Kopf M. Lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J Immunol 1999; 163:1128–1131.
92. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, et al
. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006; 176:6752–6761.
93. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al
. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003; 100:8372–8377.
94. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 2005; 175:7746–7754.
95. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. The Oncologist 2007; 12:864–872.
96. Zheng SG, Wang JH, Stohl W, Kim KS, Gray JD, Horwitz DA. TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+
regulatory cells. J Immunol 2006; 176:3321–3329.
97. Munn DH, Sharma MD, Mellor AL. Ligation of B7-1/B7-2 by human CD4+
T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 2004; 172:4100–4110.
98. Boasso A, Herbeuval JP, Hardy AW, Winkler C, Shearer GM. Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+
T cells. Blood 2005; 105:1574–1581.
99. Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E, et al
. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25−
T regulatory cells. Blood 2007; 109:2871–2877.
100. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006; 27:195–201.
101. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007; 8:239–245.
102. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al
. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443:350–354.
103. Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, Adams WC, et al
. PD-1 is a regulator of virus-specific CD8+
T cell survival in HIV infection. J Exp Med 2006; 203:2281–2292.
104. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, et al
. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006; 12:1198–1202.
105. Raimondi G, Shufesky WJ, Tokita D, Morelli AE, Thomson AW. Regulated compartmentalization of programmed cell death-1 discriminates CD4+
resting regulatory T cells from activated T cells. J Immunol 2006; 176:2808–2816.
106. Cabrera R, Tu Z, Xu Y, Firpi RJ, Rosen HR, Liu C, Nelson DR. An immunomodulatory role for CD4+
regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004; 40:1062–1071.
107. Bolacchi F, Sinistro A, Ciaprini C, Demin F, Capozzi M, Carducci FC, et al
. Increased hepatitis C virus (HCV)-specific CD4+
regulatory T lymphocytes and reduced HCV-specific CD4+
T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels. Clin Exp Immunol 2006; 144:188–196.
108. Manigold T, Shin EC, Mizukoshi E, Mihalik K, Murthy KK, Rice CM, et al
T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C. Blood 2006; 107:4424–4432.
109. Miedema F, Petit AJ, Terpstra FG, Schattenkerk JK, de Wolf F, Al BJ, et al
. Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+
T helper cell depletion occurs. J Clin Invest 1988; 82:1908–1914.
110. Oswald-Richter K, Grill SM, Shariat N, Leelawong M, Sundrud MS, Haas DW, Unutmaz D. HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells. PLoS Biol 2004; 2:e198.
111. Kinter AL, Hennessey M, Bell A, Kern S, Lin Y, Daucher M, et al
regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4+
HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med 2004; 200:331–343.
112. Weiss L, Donkova-Petrini V, Caccavelli L, Balbo M, Carbonneil C, Levy Y. Human immunodeficiency virus-driven expansion of CD4+
regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood 2004; 104:3249–3256.
113. Eggena MP, Barugahare B, Jones N, Okello M, Mutalya S, Kityo C, et al
. Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol 2005; 174:4407–4414.
114. Andersson J, Boasso A, Nilsson J, Zhang R, Shire NJ, Lindback S, et al
. The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J Immunol 2005; 174:3143–3147.
115. Tsunemi S, Iwasaki T, Imado T, Higasa S, Kakishita E, Shirasaka T, Sano H. Relationship of CD4+
regulatory T cells to immune status in HIV-infected patients. AIDS 2005; 19:879–886.
116. Apoil P, Piussant B, Roubinet F, Abbal M, Massip P, Blancher A. FOXP3 mRNA levels are decreased in peripheral blood CD4+
lymphocytes from HIV-positive patients. J Acquir Immune Defic Syndr 2005; 39:381–385.
117. Krathwohl MD, Schacker TW, Anderson JL. Abnormal presence of semimature dendritic cells that induce regulatory T cells in HIV-infected subjects. J Infect Dis 2006; 193:494–504.
118. Estes JD, Li Q, Reynolds MR, Wietgrefe S, Duan L, Schacker T, et al
. Premature induction of an immunosuppressive regulatory T cell response during acute simian immunodeficiency virus infection. J Infect Dis 2006; 193:703–712.
119. Epple HJ, Loddenkemper C, Kunkel D, Troeger H, Maul J, Moos V, et al
. Mucosal but not peripheral FOXP3+
regulatory T cells are highly increased in untreated HIV infection and normalize after suppressive HAART. Blood 2006; 108:3072–3078.
120. Montes M, Lewis DE, Sanchez C, de Castilla DL, Graviss EA, Seas C, et al
regulatory T cells in antiretroviral-naive HIV patients. AIDS 2006; 20:1669–1671.
121. Lim AY, Price P, Beilharz MW, French MA. Cell surface markers of regulatory T cells are not associated with increased forkhead box p3 expression in blood CD4+ T cells from HIV-infected patients responding to antiretroviral therapy. Immunol Cell Biol 2006; 84:530–536.
122. Nilsson J, Boasso A, Velilla PA, Zhang R, Vaccari M, Franchini G, et al
. HIV-1 driven regulatory T cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood 2006; 108:3808–3817.
123. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, et al
T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749–759.
124. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, Knight HL, et al
. Gastrointestinal tract as a major site of CD4+
T cell depletion and viral replication in SIV infection. Science 1998; 280:427–431.
125. Zaunders JJ, Ip S, Munier ML, Kaufmann DE, Suzuki K, Brereton C, et al
. Infection of CD127+
T cells and over-expression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary HIV-1 infection. J Virol 2006; 80:10162–10172.
126. Grant C, Oh U, Fugo K, Takenouchi N, Griffith C, Yao K, et al
. Foxp3 represses retroviral transcription by targeting both NF-kappaB and CREB pathways. PLoS Pathog 2006; 2:e33.
127. Hsieh SM, Chen MY, Pan SC, Hung CC, Chang SC. Aberrant induction of regulatory activity of CD4+
T cells by dendritic cells in HIV-infected persons with amebic liver abscess. J Acquir Immune Defic Syndr 2007; 44:6–13.
128. Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF. Human CD4+
regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 2004; 78:2454–2459.
129. Jesser RD, Li S, Weinberg A. Regulatory T cells generated during cytomegalovirus in vitro stimulation of mononuclear cells from HIV-infected individuals on HAART correlate with decreased lymphocyte proliferation. Virology 2006; 352:408–417.
130. Legrand FA, Nixon DF, Loo CP, Ono E, Chapman JM, Miyamoto M, et al
. Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal. PLoS ONE 2006; 1:e102.
131. Kinter A, McNally J, Riggin L, Jackson R, Roby G, Fauci AS. Suppression of HIV-specific T cell activity by lymph node CD25+
regulatory T cells from HIV-infected individuals. Proc Natl Acad Sci U S A 2007; 104:3390–3395.
132. Kinter AL, Horak R, Sion M, Riggin L, McNally J, Lin Y, et al
regulatory T cells isolated from HIV-infected individuals suppress the cytolytic and nonlytic antiviral activity of HIV-specific CD8+
T cells in vitro
. AIDS Res Hum Retroviruses 2007; 23:438–450.
133. Elrefaei M, Ventura FL, Baker CA, Clark R, Bangsberg DR, Cao H. HIV-specific IL-10-positive CD8+
T cells suppress cytolysis and IL-2 production by CD8+
T cells. J Immunol 2007; 178:3265–3271.
134. Baker CA, Clark R, Ventura F, Jones NG, Guzman D, Bangsberg DR, Cao H. Peripheral CD4 loss of regulatory T cells is associated with persistent viraemia in chronic HIV infection. Clin Exp Immunol 2007; 147:533–539.
135. Kornfeld C, Ploquin MJ, Pandrea I, Faye A, Onanga R, Apetrei C, et al
. Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J Clin Invest 2005; 115:1082–1091.
136. Estes JD, Wietgrefe S, Schacker T, Southern P, Beilman G, Reilly C, et al
. Simian immunodeficiency virus-induced lymphatic tissue fibrosis is mediated by transforming growth factor beta 1-positive regulatory T cells and begins in early infection. J Infect Dis 2007; 195:551–561.
137. Hryniewicz A, Boasso A, Edghill-Smith Y, Vaccari M, Fuchs D, Venzon D, et al
. CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood 2006; 108:3834–3842.
138. Potula R, Poluektova L, Knipe B, Chrastil J, Heilman D, Dou H, et al
. Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood 2005; 106:2382–2390.
139. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, et al
. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115:3623–3633.
140. Kocak E, Lute K, Chang X, May KF Jr, Exten KR, Zhang H, et al
. Combination therapy with anti-CTL antigen-4 and anti4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res 2006; 66:7276–7284.
141. Colle JH, Moreau JL, Fontanet A, Lambotte O, Joussemet M, Jacod S, et al
. Regulatory dysfunction of the interleukin-7 receptor in CD4 and CD8 lymphocytes from HIV-infected patients-effects of antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 42:277–285.
142. Napolitano LA, Grant RM, Deeks SG, Schmidt D, De Rosa SC, Herzenberg LA, et al
. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med 2001; 7:73–79.
143. Smithgall MD, Wong JG, Critchett KE, Haffar OK. IL-7 up-regulates HIV-1 replication in naturally infected peripheral blood mononuclear cells. J Immunol 1996; 156:2324–2330.
144. Chene L, Nugeyre MT, Guillemard E, Moulian N, Barre-Sinoussi F, Israel N. Thymocyte-thymic epithelial cell interaction leads to high-level replication of human immunodeficiency virus exclusively in mature CD4+
thymocytes: a critical role for tumor necrosis factor and interleukin-7. J Virol 1999; 73:7533–7542.
145. Rosenberg SA, Sportes C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, et al
. IL-7 administration to humans leads to expansion of CD8+
cells but a relative decrease of CD4+
T-regulatory cells. J Immunother 2006; 29:313–319.
146. Beq S, Nugeyre MT, Ho Tsong Fang R, Gautier D, Legrand R, Schmitt N, et al
. IL-7 induces immunological improvement in SIV-infected rhesus macaques under antiviral therapy. J Immunol 2006; 176:914–922.